537013-51-7

Basic information

• Product Name: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE
• Synonyms: 4-BROMO-2,6-DIFLUOROBENZALDEHYDE;4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE;Benzaldehyde, 4-broMo-2,6-difluoro-;4-Bromo-2,6-difluorobenzaldehyde 96%
• CAS NO: 537013-51-7
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 221
• EINECS: 1308068-626-2
• Product Categories: Benzaldehyde
• Mol File: 537013-51-7.mol
• Article Data: 29

Chemical Properties

• Melting Point: 76-79°C
• Boiling Point: 231.4±40.0℃ (760 Torr)
• Flash Point: 93.7±27.3℃
• Appearance: /
• Density: 1.758±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.063mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(537013-51-7)
• EPA Substance Registry System: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(537013-51-7)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 537013-51-7(Hazardous Substances Data)

Usage

Uses

4-Bromo-2,6-difluorobenzaldehyde can be used as organic synthesis and pharmaceutical intermediates, mainly in laboratory research and development, chemical and pharmaceutical production processes.

Synthesis

n-Butyl lithium (0.64ml, 1.2 mmol) was added drop wise to a solution of diisopropyl amine (0.25 mL, 1.5 mmol) in dry THF at -78°C under nitrogen atmosphere over a period of 5 minutes. The reaction mixture was stirred at -20°C for 30 minutes. To this was added 5-bromo-benzo[b]thiophene (200 mg, 0.938 mmol) in dry THF at -78°C, continued stirring for a further 30 minutes at -78°C, followed by the addition of N-chlorosuccinamide (225 mg, 1.68 mmol) in dry THF at -78°C. The resulting mixture was stirred at room temperature for 2 hours. The reaction was monitored by TLC (100% hexane). The reaction mixture was partitioned between ethyl acetate and saturated ammonium chloride. The organic layer was dried over sodium sulfate and concentrated to afford the crude product. Purification by column chromatography on silica gel (100% hexane) afforded the product. Preparation of Intermediate 4-Bromo-2,6-difluoro-benzaldehyde (I-26a): Using analogous reaction condition and reagents as described in Example 20 for the preparation of 1-20a above, 1-bromo-3,5-difluoro-benzene (2 g, 2.10.36 mmol) in THF was reacted with DMF (1.43 g,19.68 mmol), n-butyl lithium (1.56 ml, 12.4 mmol) and diisopropyl amine (0.57 mL, 15.5 mmol) to afford crude product. Purification by column chromatography on silica gel (2% ethyl acetate in hexane) afforded 1.35 g of the product (61% yield). 1H NMR (CDCl3, 300 MHz): δ 11.5-11.0 (s, 1H), 7.4-7.2 (dd, 2H).

InChI:InChI=1/C7H3BrF2O/c8-4-1-6(9)5(3-11)7(10)2-4/h1-3H

Upstream product

• 2591-86-8 N-Formylpiperidine 
• 461-96-1 3,5-difluorobromobenzene 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 64-19-7 acetic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 

Downstream Products

• 1027215-37-7 (4-bromo-2,6-difluoro-benzyl)-(3-methyl-butyl)-amine 
• 1093878-13-7 5-bromo-1,3-difluoro-2-(2-methoxyvinyl)benzene 
• 844850-00-6 ethyl 3-(4-bromo-2,6-difluorophenyl)-2-methylacrylate 
• 1093878-14-8 2-(3,5-difluoro-4-(2-methoxyvinyl)phenyl)propan-2-ol 
• 1093878-15-9 (2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl)acetaldehyde 
• 1093878-16-0 2-amino-5-(2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl)thiophene-3-carboxamide 
• 1201924-05-1 5-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-{[6-(2-hydroxyethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl]amino}thiophene-3-carboxamide 
• 1639042-08-2 (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid 
• 1007580-15-5 5-(4-formylphenyl)-3-pyridinecarboxamide 

Relevant articles and documents

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodoma in-containing protein 9 (BRD9)

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.